A novel, spontaneously immortalized, human prostate cancer cell line, bob, offers a unique model for pre-clinical prostate cancer studies

Prostate

Volumn 69, Issue 14, 2009, Pages 1507-1520

  Attard, Gerhardt ^a,b   Rizzo, Sian ^a   Ledaki, Ioanna ^a   Clark, Jeremy ^a   Reid, Alison H M ^a,b   Thompson, Alan ^b   Khoo, Vincent ^b   De Bono, Johann S ^a,b   Cooper, Colin S ^a   Hudson, David L ^a,c  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF YORK   (United Kingdom)

Author keywords

8(q) copy number gain; Basal; Cancer cell lines; Castration resistant prostate cancer

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; COLLAGENASE; CYTOKINE; METHYLCELLULOSE; PROSTATE STEM CELL ANTIGEN; PROTEIN P53;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CANCER MODEL; CANCER RESISTANCE; CANCER SURVIVAL; CASTRATION; CELL CLONE; CELL DIFFERENTIATION; CELL IMMORTALIZATION; CELL SURVIVAL; COMPARATIVE GENOMIC HYBRIDIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; KERATINOCYTE; MALE; MOUSE; NEEDLE BIOPSY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE TUMOR; PROTEIN EXPRESSION;

ANIMALS; BIOPSY, NEEDLE; BLOOD PROTEINS; CELL ADHESION; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL DIVISION; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL MOVEMENT; CELL SEPARATION; COMPARATIVE GENOMIC HYBRIDIZATION; DNA, NEOPLASM; EUKARYOTIC INITIATION FACTOR-3; HUMANS; KARYOTYPING; MALE; METHYLCELLULOSE; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; PHENOTYPE; PROSTATIC NEOPLASMS; SPHEROIDS, CELLULAR;

EID: 69449084813     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20997     Document Type: Article

References (22)

1. Pienta KJ, Abate-Shen C, Agus DB, Attar RM, Chung LW, Greenberg NM, Hahn WC, Isaacs JT, Navone NM, Peehl DM, Simons JW, Solit DB, Soule HR, VanDyke TA, Weber MJ, Wu L, Vessella RL. The current state of preclinical prostate cancer animal models. Prostate 2008;68(6):629-639. (Pubitemid 351614641)
2. Korenchuk S, Lehr JE, MC L, Lee YG, Whitney S, Vessella R, Lin DL, Pienta KJ. VCaP, a cell-based model system of human prostate cancer. In Vivo 2001;15(2):163-168. (Pubitemid 32328191)
3. Lee YG, Korenchuk S, Lehr J, Whitney S, Vessela R, Pienta KJ. Establishment and characterization of a new human prostatic cancer cell line: DuCaP. In Vivo 2001;15(2):157-162. (Pubitemid 32328190)
4. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 1978;21(3):274-281. (Pubitemid 8283045)
5. Rhim JS. Development of human cell lines from multiple organs. Ann NY Acad Sci 2000;919:16-25. (Pubitemid 30944914)
6. Shepherd CJ, Rizzo S, Ledaki I, Davies M, Brewer D, Attard G, de Bono J, Hudson DL. Expression profiling of CD133+ and CD133- epithelial cells from human prostate. Prostate 2008;68(9):1007-1024.
7. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17(11):3461-3467. (Pubitemid 29517916)
8. Alam TN, O'Hare MJ, Laczko I, Freeman A, Al-Beidh F, Masters JR, Hudson DL. Differential expression of CD44 during human prostate epithelial cell differentiation. J Histochem Cytochem 2004;52(8):1083-1090. (Pubitemid 38982197)
9. Natrajan R, Williams RD, Hing SN, Mackay A, Reis-Filho JS, Fenwick K, Iravani M, Valgeirsson H, Grigoriadis A, Langford CF, Dovey O, Gregory SG, Weber BL, Ashworth A, Grundy PE, Pritchard-Jones K, Jones C. Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse. J Pathol 2006;210(1):49-58. (Pubitemid 44288180)
10. Lambros MB, Simpson PT, Jones C, Natrajan R, Westbury C, Steele D, Savage K, Mackay A, Schmitt FC, Ashworth A, Reis-Filho JS. Unlocking pathology archives for molecular genetic studies: A reliable method to generate probes for chromogenic and fluorescent in situ hybridization. Lab Invest 2006;86(4):398-408.
11. Wang Y, Revelo MP, Sudilovsky D, Cao M, Chen WG, Goetz L, Xue H, Sadar M, Shappell SB, Cunha GR, Hayward SW. Development and characterization of efficient xenograft models for benign and malignant human prostate tissue. Prostate 2005;64(2):149-159. (Pubitemid 40791764)
12. Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P, Berney D, Foster CS, Fletcher A, Gerald WL, Moller H, Reuter V, De Bono JS, Scardino P, Cuzick J, Cooper CS. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008;27(3):253-263.
13. Attard G, Clark J, Ambroisine L, Mills IG, Fisher G, Flohr P, Reid A, Edwards S, Kovacs G, Berney D, Foster C, Massie CE, Fletcher A, De Bono JS, Scardino P, Cuzick J, Cooper CS. Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer. Br J Cancer 2008;99(2):314-320.
14. Tay Y, Zhang J, Thomson AM, Lim B, Rigoutsos I. MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature 2008;455(7216):1124-1128.
15. Kasahara K, Taguchi T, Yamasaki I, Kamada M, Yuri K, Shuin T. Detection of genetic alterations in advanced prostate cancer by comparative genomic hybridization. Cancer Genet Cytogenet 2002;137(1):59-63.
16. Sun J, Liu W, Adams TS, Li X, Turner AR, Chang B, Kim JW, Zheng SL, Isaacs WB, Xu J. DNA copy number alterations in prostate cancers: A combined analysis of published CGH studies. Prostate 2007;67(7):692-700. (Pubitemid 46709438)
17. Haapala K, Rokman A, Palmberg C, Hyytinen ER, Laurila M, Tammela TL, Koivisto PA. Chromosomal changes in locally recurrent, hormone-refractory prostate carcinomas by karyotyping and comparative genomic hybridization. Cancer Genet Cytogenet 2001;131(1):74-78. (Pubitemid 33081162)
18. Griewe GL, Dean RC, Zhang W, Young D, Sesterhenn IA, Shanmugam N, McLeod DG, Moul JW, Srivastava S. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein. Prostate Cancer Prostatic Dis 2003;6(4):281-285. (Pubitemid 38088189)
19. Anzola M, Saiz A, Cuevas N, Lopez-Martinez M, Martinez de Pancorbo MA, Burgos JJ. High levels of p53 protein expression do not correlate with p53 mutations in hepatocellular carcinoma. J Viral Hepat 2004;11(6):502-510. (Pubitemid 39486613)
20. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65(23):10946-10951. (Pubitemid 41713363)
21. Miki J, Furusato B, Li H, Gu Y, Takahashi H, Egawa S, Sesterhenn IA, McLeod DG, Srivastava S, Rhim JS. Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res 2007;67(7):3153-3161. (Pubitemid 46724852)
22. Jaksch M, Munera J, Bajpai R, Terskikh A, Oshima RG. Cell cycle-dependent variation of a CD133 epitope in human embryonic stem cell, colon cancer, and melanoma cell lines. Cancer Res 2008;68(19):7882-7886.